Incidence and Paris Classification of Pediatric Inflammatory Bowel Disease
Table 4
Paris Classification of patients with Crohn’s disease in population-based studies in Europe [3, 32, 34, 57, 58].
North-Eastern Slovenia
Northern Stockholm
Eurokids
Hungary (HUPIR)
Ireland
Crohn’s disease ()
43
96
582
247
31
Age, % (/)
A1a
15
—
20% (244/1221)
11% (27/247)
26% (8/31)
A1b
—
—
80%
78% (197/247)
74% (23/31)
A2
—
—
9% (23/247)
Location, % (/)
L1*
20.9% (9/43)
8% (8/96)
16%
13.4% (33/247)
19% (6/31)
L1 + L4a
2.3%
—
3.6% (21)
L1 + L4b
0
—
3.4% (20)
3% (7/247)
13% (4/31)
L1 + L4ab
7%
—
1.4% (8)
*L2
4.6% (2/43)
71% (68/96)
28% (159/582)
27.5% (68/247)
45% (14/31)
L2 + L4a
0
—
4.1% (24/582)
L2 + L4b
0
—
3.8% (22/582)
6.8% (17/247)
3% (1/31)
L2 + L4ab
0
—
1.2% (7/582)
*L3
74.5% (32/43)
20% (19/96)
53%
58.7% (145/247)
32% (10/31)
L3 + L4a
23.3%
—
14.3%
L3 + L4b
11.6%
—
6.5%
49
16% (5/31)
L3L4ab
16.3%
—
4.3%
L4 (Isolated)
0
0
4% (18/582)
0.4% (1/247)
3% (1/31)
All upper gastrointestinal involvement
0.4% (1/247)
L4a
48.9% (21/43)
17% (16/96)
L4b
34.9% (15/43)
1% (1/96)
Behaviour
B1
86% (56/65)
95% (91/96)
82% (959/1177)
12.1% (216/256)
90% (28/31)
B2
6% (4/65)
5% (5)
12% (144/1177)
2.3% (31/256)
6% (2/31)
B3
8% (5/65)
0
5% (55/1177)
1.2% (6/256)
3% (1/31)
B2B3
—
0
2% (19/1177)
0.6% (3/256)
—
Perianal disease
—
8% (8/96)
9% (114/1207)
14.5% (37/247)
10% (3/31)
Growth (G1) G1
6.6% (16/244)
23% (4/31)
L1 + L4a, L1 + L4b, and L1 + L4ab patients are included in patients with L1 location. A1a: 0–<10 years, A1b: 10–<17 years, and A2: 17–<40 years. B1: nonstricturing-nonpenetrating; B2: stricturing; B3: penetrating; B2B3: both penetrating and stricturing; G1: evidence of growth delay; L1: distal 1/3 ileal disease (limited cecal disease); L2: colonic disease; L3: ileocolonic disease; L4: upper gastrointestinal tract disease; L4a: esophagogastroduodenal disease proximal to ligament of Treitz; L4b: distal to ligament of Treitz.
